arrow_back Back Filing freshness 10-Q Q2 FY2025 SEC EDGAR

Adaptimmune Therapeutics PLC

ADAPY
Price unavailable
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
45 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
20
Health
Poor
Bearish
auto_awesome

Analytical Summary

Adaptimmune Therapeutics PLC faces fundamental challenges with weakness in Profit Margin (%) and Debt to Equity. The fundamentals warrant careful consideration of downside risks.

Market Cap
Dividend Yield
Revenue Growth -89.3%
Op. Margin -221.5%
ROIC 68.3%
FCF / Share $-0.02
Trailing P/E
Price / Book
FCF Yield
Debt / Equity -0.36
info Valuation on last close.

45-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$13.68M
↓ -89.3%
Net Income Profit after all expenses
$-47.58M
↑ +1.9%
Operating Margin Operating profit as % of sales
-221.5%
↓ -517.0% 7th
FCF / Share Free cash flow per share
$-0.02
↑ +50.0%
Long-Term Debt Long-term obligations
$25.68M
↑ +1.0%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Debt to EquityDebt to Equity is concerning (bottom quartile)
  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability
7
Financial Health
13
Cash Quality
68

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 13 years · 45 quarters